Mortimer, Joanne E <br/><br/>
Safety considerations for use of bone-targeted agents in patients with cancer.  [electronic resource] 

 -  Seminars in oncology  Jun 2010 
 - S66-72 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1532-8708 
<br/><br/><label>Standard No.: </label>10.1053/j.seminoncol.2010.06.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Bone Density Conservation Agents--adverse effects<br/>Bone Neoplasms--prevention & control<br/>Bone and Bones--drug effects<br/>Denosumab<br/>Diphosphonates--adverse effects<br/>Fever--chemically induced<br/>Gastrointestinal Diseases--chemically induced<br/>Humans<br/>Kidney Diseases--chemically induced<br/>Neoplasms--drug therapy<br/>RANK Ligand--adverse effects